Unexpected doxorubicin-mediated cardiotoxicity in sisters: Possible role of polymorphisms in histamine n-methyl transferase

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 3, 2013, Pages 269-272

  Sachidanandam, Kamakshi ^a   Gayle, Arlene A ^b   Robins, H Ian ^b,c   Kolesar, Jill M ^a,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

cardiotoxicity; Doxorubicin; polymorphism

Indexed keywords

DOXORUBICIN; HISTAMINE METHYLTRANSFERASE;

ARTICLE; CARDIOTOXICITY; CASE REPORT; DRUG SAFETY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

CARDIOTOXICITY; DOXORUBICIN; POLYMORPHISM;

ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTOXINS; DOXORUBICIN; FEMALE; GENOTYPE; HEART DISEASES; HISTAMINE N-METHYLTRANSFERASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIBLINGS;

EID: 84882289013     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212461022     Document Type: Article

References (15)

1. Gianni L, Herman E, Lipshultz S, et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008 ; 26: 3777-3784
2. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007 ; 23: 15-25
3. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicininduced cardiotoxicity. Circulation. 2005 ; 112: 3754-3762
4. Couture L, Nash JA, Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev. 2006 ; 58: 244-258
5. Dell'Acqua G, Polishchuck R, Fallon JT, et al. Cardiac resistance to adriamycin in transgenic mice expressing a rat alpha-cardiac myosin heavy chain/human multiple drug resistance 1 fusion gene. Hum Gene Ther. 1999 ; 10: 1269-1279
6. Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol. 2007 ; 7: 129-134
7. Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol. 1997 ; 23: 775-782
8. Ambrosone CB, Ahn J, Singh KK, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res. 2005 ; 65: 1105-1111
9. Forrest GL, Gonzalez B, Tseng W, et al. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res. 2000 ; 60: 5158-5164
10. Slupe A, Williams B, Larson C, et al. Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase. Cardiovasc Toxicol. 2005 ; 5: 365-376
11. Olson LE, Bedja D, Alvey SJ, et al. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 2003 ; 63: 6602-6606
12. Gayle AA, Sachidanandam K, Kolesar JM, et al. Unexpected doxorubicin-induced cardiomyopathy in sisters. Int Canc Conf J. 2012 ; 1: 15-18
13. Visscher H, Ross CJD, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012 ; 30: 1422-1428
14. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes - a report from the Children's Oncology Group. J Clin Oncol. 2012 ; 30: 1415-1421
15. Zhang Y, Berger SA. Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo. Cancer Chemother Pharmacol. 2003 ; 51: 407-414